Within the frame of its long-term partnership with Kamada, an Israeli company in the plasma-derived therapy field, Kedrion has confirmed the two-year extension of the distribution agreement between the parties in the US for KEDRAB® (Rabies Immune Globulin [Human]).
The current agreement now extends through March 2026, and the companies are in discussions to potentially further expand the scope of the collaboration.
Rabies remains a global public health concern that is responsible for more than 59,000 human deaths per year. An estimated up to near 60,000 Americans receive Rabies post exposure prophylaxis each year.
The partnership between Kedrion and Kamada has played a crucial role in co-developing and licensing this product in the US and also, through disease awareness campaigns, in managing to help people who have been exposed to the bite of a rabid wild animal to prevent serious and potentially life-threatening conditions.
Kedrion started the distribution of this product in March 2018. In 2021, Kedrion and Kamada announced that the US Food and Drug Administration (FDA) approved a label update for this product, establishing the product’s safety and effectiveness in children.
